Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ZS Pharma

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

China flag thumb

AstraZeneca sets sights on China with Takeda deal

Buys the Japanese firm's respiratory drugs to extends their ongoing biologics R&D collaboration

- PMLiVE

AZ confirms interest in Acerta takeover

Possible acquisition of Netherlands-based cancer drug developer may be worth more than $5bn

- PMLiVE

NICE changes stance on AZ’s Lynparza after concessions

NHS patients in England and Wales to get ovarian cancer drug

- PMLiVE

UK patients get early access to AZ’s lung cancer drug Tagrisso

The treatment is the fourth made available under the EAMS

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

Sanofi reception

Sanofi and AstraZeneca agree massive compound swap deal

Will exchange over 200,000 compounds in a new open innovation collaboration

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

- PMLiVE

AZ’s Mene Pangalos joins Precision Medicine Catapult board

Has also been appointed a fellow at the University of Cambridge

- PMLiVE

GSK and AZ drugs impress in lupus trials

Raises hope for better treatment for debilitating disease

- PMLiVE

AZ boosts cardio-renal portfolio with $2.7bn ZS Pharma buy

Acquires rights to potential best-in-class treatment for hyperkalaemia

- PMLiVE

AstraZeneca backs heart website

Works with charity HEART UK on How Young My Heart

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links